Kyverna Therapeutics, Inc.
miv-cel
stiff person syndrome
Date
TBD
Phase 2 readout · Date TBD estimated
What's at stake
Phase 2 trial results for miv-cel in stiff person syndrome are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“In addition, the Company expects to report updated Phase 2 data from the gMG trial in 2026.”